News & Updates

Cardiopulmonary function (CPF) recovery failure at 6 months after lung cancer surgery appears to be driven by reductions in lung function and moderate-to-vigorous physical activity (MVPA) from baseline to 2 weeks, suggests a study. Baseline PA and dyspnoea are also associated with the inability to recover CPF.

Patients with breast or gastrointestinal (GI) cancer who are being treated with capecitabine monotherapy may benefit from using topical diclofenac gel to prevent or reduce the incidence of hand-foot syndrome (HFS), a common side effect of some chemotherapy drugs, reports a recent study presented at ESMO 2023.

First-line treatment with TST001 (osemitamab) in combination with capecitabine and oxaliplatin (CAPOX) is safe and well tolerated in patients with advanced gastric/gastroesophageal junction (G/GEJ) cancer, according to a study presented at ESMO 2023.

The prostate-specific membrane antigen (PSMA)–targeted radioligand, lutetium-177 (¹⁷⁷Lu)–PSMA-617, improves radiographic progression-free survival (rPFS) vs androgen receptor pathway inhibitor (ARPI) switch and has a favourable safety profile in taxane-naïve patients with metastatic castration-resistant prostate cancer (mCRPC) progressing on one prior second-generation ARPI, results of the phase III PSMAfore trial have shown.

Treatment with pyrotinib in combination with trastuzumab and docetaxel (tras/doc) results in longer progression-free survival (PFS) than placebo combined with tras/doc in patients with untreated HER2-positive metastatic breast cancer, a study has shown. In addition, the safely profile of tras/doc plus pyrotinib is manageable.

Patients with early-stage nonsmall cell lung cancer (NSCLC) treated with stereotactic body radiation therapy (SBRT) have similar overall survival (OS) regardless of nodal staging, reports a study. In addition, use of SBRT has shown a steady increase over the study period.